Respuesta a la carta "La evidencia publicada y las transformaciones en el abordaje de la diabetes" by Perner, Mónica Serena
LETTERS / CARTAS 281
SA
LU
D
 C
O
LEC
TIV
A
, Buenos A
ires, 10(2):281-283. doi: 10.18294/sc.2014.307
Salud Colectiva | Universidad Nacional de Lanús | ISSN 1669-2381 | EISSN 1851-8265
for new publications other than those increas-
ingly influenced by the pharmaceutical industry, 
and above all, to create spaces for independent 
research and publications. 
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Firstly, I would like to thank María Amelia 
Linari for her letter (1) as a member of the 
Executive Committee of the Argentine Diabetes 
Society (SAD) [Sociedad Argentina de Diabetes], 
one of the institutions referred to in the article 
of my authorship published in Salud Colectiva 
(2). This scientific association was selected as 
an indispensable actor in the construction of the 
knowledge required to manage such a complex 
issue as diabetes, given both its history and its 
potential influence in health professionals in-
volved in diabetes management. Therefore, I 
believe that it is of great priority to engage in con-
versations that can further the discussion.
In this sense, Emma Dominguez Alonso states:
Diabetes mellitus, particularly type 2, is a 
disease whose development and evolution are 
directly related to social factors. Unhealthy 
lifestyles, lack of indispensable knowledge 
for the prevention and adequate control of 
the disease, the inaccessibility of high-quality 
health care services, among others, favor the 
development of the disease and, at the same 
time, have a negative influence on the prog-
nosis. The social origin of all of these condi-
tioning factors classify diabetes mellitus, with 
ever increasing evidence, as a social disease. 
(3 p.305)
Different studies have analyzed the social de-
terminants, showing, for instance, the impact that 
differences in body weight (as marker of the socio-
economic differences) have in the incidence of (4) 
and mortality due to type 2 diabetes (5).
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Additionally, type 2 diabetes is not distributed 
equally among different social groups: it shows a 
larger incidence, greater complications and higher 
mortality rates in those with lower socioeconomic 
levels as well as among women and ethnic mi-
norities (6). Possible explanations for this social 
pattern of diabetes have been given, such as the 
availability and accessibility of food and areas in 
which to carry out physical activity, differences in 
access to health care and health information, and 
healthy behaviors within the different socioeco-
nomic groups (4).
Nancy Fleischer and Ana Diez Roux mention 
that “the information available since the beginning 
of the 1960s shows that a low socioeconomic level 
[…] is generally associated with greater morbidity 
and mortality due to heart disease in  high-income 
countries” (7 p.642). There is an increasing amount 
of research showing the effect of social inequities 
in cardiovascular disease in high-income countries 
but, according to these authors’ review (7), these 
types of studies are scarce in Latin America, where 
“in general, particularly with respect to obesity, 
diabetes and diet, health inequalities were more 
pronounced among women and in urban areas” 
(7 p.644).
In this respect, I agree with María Amelia Linari 
when she claims that it is “crucial to understand in 
depth the factors that can be beneficial or harmful 
to health” (1 p.279). Therefore, I believe we should 
deepen our knowledge regarding inequalities in 
health care. I also agree that we need to individu-
alize treatment according to the “characteristics, 
conditions and history of each diabetes patient” 
(1 p.280). In order to deal comprehensively with 
such a complex issue as diabetes, it is important to 
gather information at the local level. We need to 
build strategies and interventions at the individual 
level but that are at the same time are articulated 
with population level; that is, we must have an 
individualized approach with a focus on health 
inequalities, according to the profile of our 
population.
In the approach to diabetes (prevention, 
diagnosis and treatment), it is important to re-
consider these concepts. Many innovations and 
therapeutic changes have been contributions 
of great value and practical application, with 
great impact on the quality of life of those with 
diabetes. However, innovations that approach 
diabetes from a health inequalities perspective 
are few.
In Carlos Tajer’s words, as long as the phar-
maceutical industry remains “one of the most lu-
crative, with high profitability for shareholders,” 
it will promote the incorporation of discoveries 
“within a context of growing health care costs.” 
For this reason, “many clinical trials are concep-
tually oriented towards the positioning of the drug 
in the market rather than the specific interests of 
the patient or the community” (8 p.277).
According to Maarten Boers, cited by Antonio 
Ugalde and Nuria Homedes (8), “the enormous fi-
nancial interests involved in the development of 
new drugs exert pressure on the scientific analysis 
and the presentation of the results obtained from 
the most important clinical trials” (9 p.311). In so 
doing, economic benefits take priority over the 
need to address health issues. 
If research is funded by the pharmaceu-
tical industry, the profit motive will come 
first. Consequently, the focus will be placed 
on treatment with drugs, the incorporation of 
new drugs and the initiation of pharmacologic 
treatment as early into the disease as possible, re-
ducing the values considered normal to include 
more people as diabetic in early drug treatment.
REFERENCES
1. Linari MA. La evidencia publicada y las transforma-
ciones en el abordaje de la diabetes. Salud Colectiva. 
2014;10(2):279-281.
2. Perner MS. Transformaciones en el abordaje de la 
diabetes: análisis de las evidencias científicas publicadas 
por dos sociedades científicas (1980-2010). Salud Co-
lectiva. 2013;9(3):373-389.
3. Dominguez AE. Desigualdades sociales y diabetes 
mellitus. Revista Cubana de Endocrinología [Internet]. 
2013 [cited 21 May 2014];24(2):200-213. Available 
from: http://scielo.sld.cu/pdf/end/v24n2/end09213.pdf.
4. Stringhini S, Tabak A, Akbaraly T, Sabia S, Shipley M, 
Marmot M, Brunner E, Batty D, Bovel P, Kivimäki M. Con-
tribution of modifiable risk factors to social inequalities 
in type 2 diabetes: prospective Whitehall II cohort study. 
British Medical Journal [Internet]. 2012 [cited 21 May 
2014];345:e5452. Available from: http://www.ncbi.nlm.
nih.gov/pmc/articles/PMC3424226/pdf/bmj.e5452.pdf.
5. Franco M, Bilal U, Orduñez P, Benet M, Morejón A, 
Caballero B, Cooper R. Population-wide weight loss and 
regain in relation to diabetes burden and cardiovascular 
LETTERS / CARTAS 283
SA
LU
D
 C
O
LEC
TIV
A
, Buenos A
ires, 10(2):281-283. doi: 10.18294/sc.2014.307
Salud Colectiva | Universidad Nacional de Lanús | ISSN 1669-2381 | EISSN 1851-8265
mortality in Cuba 1980-2010: repeated cross sectional 
surveys and ecological comparison of secular trends. 
British Medical Journal [Internet]. 2013 [cited 21 May 
2014];346:f1515. Available from:  http://www.bmj.com/
content/346/bmj.f1515.pdf%2Bhtml.
6. Ricci-Cabello I, Ruiz-Pérez I, Orly de Labry-Lima A, 
Marquez-Calderón S. Do social inequalities exist in terms 
of the prevention, diagnosis, treatment, control and moni-
toring of diabetes? A systematic review. Health and Social 
Care in the Community [Internet]. 2010 [cited 21 May 
2014];18(6):572-587. Available from: http://onlinelibrary.
wiley.com/doi/10.1111/j.1365-2524.2010.00960.x/pdf.
7. Fleischer N, Diez Roux AV. Inequidades en enferme-
dades cardiovasculares en Latinoamérica. Revista Peruana 
de Medicina Experimental y Salud Pública [Internet]. 
2013 [cited 21 May 2014];30(4):641-648. Available from: 
http://www.scielosp.org/pdf/rpmesp/v30n4/a17v30n4.
pdf.
8. Tajer C. Una era compleja en la interpretación de 
las evidencias científi cas en cardiología. Revista de la 
Federación Argentina de Cardiología [Internet]. 2008 
[cited 21 May 2014];37(4):276-282. Available from: 
http://www.fac.org.ar/1/revista/08v37n4/art_opinion/
opinion01/tajer.pdf.
9. Ugalde A, Homedes N. Medicamentos para lucrar: 
La transformación de la industria farmacéutica. Salud 
Colectiva [Internet]. 2009 [cited 21 May 2014];5(3):305-
322. Available from: http://www.unla.edu.ar/saludco-
lectiva/revista15/1.pdf.
CITATION
Perner MS. Response to “Published evidence and trans-
formations in the management of diabetes”. Salud Co-
lectiva. 2014;10(2):281-283
Content is licensed under a Creative Commons
Attribution — You must attribute the work in the manner specifi ed by the author or licensor (but not 
in any way that suggests that they endorse you or your use of the work). 
Noncommercial — You may not use this work for commercial purposes.
The translation of this article is part of an interdepartmental collaboration between the Undergraduate Program in 
Sworn Translation Studies (English <> Spanish) and the Institute of Collective Health at the Universidad Nacional de 
Lanús. This article was translated by Patricia De Souza Martínez and Pamela López, reviewed by María Pibernus and 
modifi ed for publication by Vanessa Di Cecco.
